Oberweis Asset Management Inc Collegium Pharmaceutical, Inc Transaction History

Oberweis Asset Management Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$21.74 - $25.28 $895,687 - $1.04 Million	-41,200 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$19.25 - $26.1 $92,400 - $125,280	-4,800 Reduced 10.43%	41,200 $976,000
Q4 2020 Feb 16, 2021	SELL	$17.83 - $22.29 $128,375 - $160,488	-7,200 Reduced 13.53%	46,000 $921,000
Q2 2020 Aug 14, 2020	SELL	$15.49 - $23.51 $15,490 - $23,510	-1,000 Reduced 1.85%	53,200 $931,000
Q1 2020 May 15, 2020	BUY	$13.89 - $25.45 $109,731 - $201,055	7,900 Added 17.06%	54,200 $885,000
Q4 2019 Feb 14, 2020	BUY	$10.7 - $22.24 $495,409 - $1.03 Million	46,300 New	46,300 $953,000

247

37.4M

59.3K

9.5K

Ticker COLL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 34,126,200
Market Cap $1.02B
Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...

Get notified when there are updates to the investment portfolio of Oberweis Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Oberweis Asset Management Inc with notifications on news.